Art. -Nr.: HY-P99048

Biologically Validated

Sintilimab

(Synonyms: IBI308)

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a K_D value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.1%
CAS. Nr.: 2072873-06-2
Molecular Weight:144.04 kDa

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Sintilimab Chemical Structure

CAS. Nr.: 2072873-06-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Anwendung
- Verified Bioactivity
Chemical Information
Publications (3)
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Isotype

Human IgG4 kappa

Recommend Isotype Controls

Human IgG4 (S228P) kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

PDCD1/PD-1/CD279

In Vitro

Sintilimab (12 h) shows a high level of PD-1 occupancy and has superior T cell activating characteristics in human peripheral blood mononuclear cells (PBMCs)^[2].
Sintilimab (0.16-100 nM; 5 days) induces high secretion levels of IFN-γ and IL-2 in primary T cell assays^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Sintilimab (0.1 mg/kg, 1 mg/kg and 10 mg/kg, i.p., a single dose for 1, 8, 12, 15 days) shows antitumor effects against NCI-H292 tumors in a humanized mouse model^[2].
Sintilimab (1 mg/kg, 3 mg/kg and 10 mg/kg, s.c., a single dose) demonstrates a high affinity for PD-1 molecules in NCI-H292 tumor-bearing NOG mice^[2].
Sintilimab (20 mg/kg, i.p., once interval 2 days for 21 days) combined with prebiotics inhibits the volume of transplanted tumors in lung adenocarcinoma and alleviates the liver and kidney injury^[4].

Pharmacokinetic parameters of Sintilimab (10 mg/kg, i.v., a single dose) in hPD-1 knock-in mouse^[2]

Parameter	AUC_0-4 (h·μg/mL)	AUC_inf (h·μg/mL)	CL (mL/h)	C_max (μg/mL)	T_1/2 (h)	V_ss (mL)
Sintilimab	6597.888	7846.554	0.025	218.519	35.623	1.262

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NOG mice reconstituted with human PBMCs^[2]
Dosage:

1 mg/kg, 3 mg/kg and 10 mg/kg
Administration:

i.p., a single dose at 24 h and 72 h
Result:

Dose-dependently showed a higher percentage of PD-1 molecule occupancy compared with MDX-1106 (HY-P9903) and MK-3475 (HY-P9902) in mice.

Animal Model:

NCI-H292 tumor-bearing NOG mice^[2]
Dosage:

1 mg/kg, 3 mg/kg and 10 mg/kg
Administration:

s.c., a single dose at 24 h
Result:

Increased PD-1 receptor occupancy in both peripheral and CD3+ tumor-infiltrating T cells (TILs) to more than 90% in NCI-H292 tumor-bearing mice.

Animal Model:

NCI-H292 tumors in a humanized xenograft mouse model^[2]
Dosage:

0.1 mg/kg, 1 mg/kg and 10 mg/kg
Administration:

i.p., a single dose at day 1, 8, 12, 15
Result:

Inhibited tumor growth much more effectively and was significantly higher in the ratio of CD8+ to Treg tumor-infiltrating lymphocytes than MDX-1106 (HY-P9903) and MK-3475 (HY-P9902) in mice.

Animal Model:

C57BL/6J mice (6-8 weeks old, body mass 20-25 g) with lung adenocarcinoma^[4]
Dosage:

20 mg/kg
Administration:

i.p., once interval 2 days for 21 days
Result:

Significantly decreased the tumor volume, showed blurred cell structure and mildly damaged liver lobules and reduced liver and kidney injury in lung adenocarcinoma mice.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Gene ID

5133 [NCBI]

Accession

Q15116

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Human IgG4 kappa

Anwendung

ELISA, FACS, Functional assay

Verified Bioactivity

Immobilized PD-1 Protein, Human (143a.a, HEK293, His, HY-P7396) can bind Sintilimab. The EC₅₀ for this effect is 6.653 ng/mL.
Flow cytometric analysis of 1X10⁶ 10 ng/mL PMA and 1 μg/mL Ionomycin co-stimulated Jurkat cells(24h) labeling Sintilimab (HY-P99048, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

Chemical Information

CAS. Nr. 2072873-06-2
Appearance Liquid
Molecular Weight 144.04 kDa
Color Colorless to light yellow
SMILES

[Sintilimab]
Synonyms

IBI308
Formulation

Please refer to the lot-specific COA for specific buffer information.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (3)

All

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

Deep Learning-Powered Scalable Cancer Organ Chip for Cancer Precision Medicine. [Abstract]

2026 Feb 3:e16660. PMID: 41632021
J Nanobiotechnology

Inverse-designed plasmonic biosensors with LSPR-SPP-wood anomaly coupling enhanced for biomolecular analysis. [Abstract]

2025 Dec 16;24(1):58. PMID: 41402825
Int Immunopharmacol

PA-MSHA promotes antitumor immunity in STK11 mutant NSCLC through activating the STING pathway of immune cells. [Abstract]

2026 Jul 15:181:116763. PMID: 42070312

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (267 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

Verweise

[1]. Sheridan M Hoy. Sintilimab: First Global Approval Drugs. 2019 Feb;79(3):341-346. [Content Brief]

[2]. Wang J, et al Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. MAbs. 2019 Nov-Dec;11(8):1443-1451. [Content Brief]

[3]. Zhang L, et al. Sintilimab: A Promising Anti-Tumor PD-1 Antibody. Front Oncol. 2020 Nov 26;10:594558. [Content Brief]

[4]. Yan Q, et al. Prebiotics Modulate Gut Microbiota-mediated T-cell Immunity to Enhance the Inhibitory Effect of Sintilimab in Lewis Lung Adenocarcinoma Model Mice. Anticancer Agents Med Chem. 2023;23(17):1966-1973. [Content Brief]

[5]. Zhang L, et al. Sintilimab for the treatment of non-small cell lung cancer. Biomark Res. 2022 Apr 18;10(1):23. [Content Brief]

[6]. Lou B, et al. Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer. Front Oncol. 2021 Sep 15;11:736955. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Sintilimab

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Sintilimab

Antibody Inhibitor Library

Publications Citing Use of MedChemExpress (MCE) Sintilimab

Biologische Aktivität

Chemical Information

Publications (3)

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Sintilimab

Cell-ATP Viability Detection Kit

Protein A Agarose

HOLO Human Interleukin-2 (IL-2) Detection Kit

Bradford Protein Assay Kit

Cytotoxicity LDH Assay Kit

PBS Buffer (1×)

DPBS Buffer (1×)

Antibody Inhibitor Library

Publications Citing Use of MedChemExpress (MCE) Sintilimab

Biologische Aktivität

Chemical Information

Publications (3)

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Sintilimab Related Classifications

HY-P99048 Related Classifications